



## The Role of NGS in the Advancement of Personalized Medicine Over the Past Two Decades

Mohammad Sadra Samavati<sup>1,\*</sup>, Saeed Piri-Gharaghie<sup>2</sup>

<sup>1</sup> Department of biology, Science and culture University, Tehran, Iran.

<sup>2</sup> Department of chemistry, Asaluyeh branch of Islamic azad university, Asaluyeh, Iran.

Corresponding Author's E-mail: [sadrasamavati40@gmail.com](mailto:sadrasamavati40@gmail.com)

### Abstract:

Next-generation sequencing (NGS) has revolutionized both clinical practice and biomedical research by providing rapid, highly accurate, and high-throughput genomic analysis. This review explores the technological progression of NGS, its contribution to mapping human genomic diversity, and its growing utility in areas such as precision medicine, oncology, pharmacogenomics, the diagnosis of rare disorders, and clinical decision support. By detecting single nucleotide variants, copy number changes, structural variations, and complex genomic rearrangements, NGS has deepened our understanding of disease heterogeneity and facilitated the creation of targeted treatment plans. In the field of oncology, the adoption of NGS has improved tumor classification, enabled therapies tailored to specific genetic profiles, and allowed for real-time monitoring via circulating tumor DNA analysis.


In pharmacogenomics, NGS has improved drug response prediction by identifying both common and rare variants affecting drug metabolism. Additionally, its application in rare diseases has shortened diagnostic odysseys and accelerated novel gene discovery. Despite challenges related to data interpretation, ethical governance, regulatory oversight, and data management, continuous technological innovation and multi-omics integration are strengthening the clinical utility of NGS. Collectively, NGS serves as a foundational pillar of personalized medicine, shaping a more predictive, preventive, and precision-oriented healthcare paradigm.

**Keywords:** Next-Generation Sequencing (NGS), Personalized Medicine, Precision Diagnostics, Cancer Genomics, Pharmacogenomics.

### Introduction to Next-Generation Sequencing and Personalized Medicine

Next-Generation Sequencing (NGS) has significantly reshaped the landscape of biomedical research and clinical care by allowing for rapid, high-throughput genomic analysis with exceptional depth and precision. In contrast to conventional Sanger sequencing, NGS technologies can sequence millions of DNA fragments in parallel, which

dramatically cuts down both time and expenses while enhancing scalability. This innovation has hastened the shift from traditional medical practices to personalized medicine, a model that customizes preventive, diagnostic, and therapeutic interventions based on an individual's genetic makeup. By offering detailed insights into genomic diversity such as single nucleotide variants, copy number variations, and structural rearrangements NGS has improved



### COPYRIGHTS

The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### How to Cite this Article:

M.S. Samavati, S. Piri-Gharaghie " The Role of NGS in the Advancement of Personalized Medicine Over the Past Two Decades", Advanced Therapies Journal, vol. 8, no. 26, pp. 39-47, 2026.

our comprehension of disease heterogeneity. It is instrumental in pinpointing the molecular causes of complex conditions and discovering mutations that have clinical implications. Consequently, NGS has emerged as a cornerstone of precision diagnostics, targeted treatment selection, and risk evaluation. The incorporation of genomic data into standard clinical protocols has further bolstered the delivery of personalized healthcare, establishing NGS as a fundamental pillar of contemporary personalized medicine (1).

In the last ten years, NGS applications have moved from specialized research labs into everyday clinical environments, notably in oncology, the diagnosis of rare diseases, infectious disease monitoring, and pharmacogenomics. Within oncology, profiling tumor genomes via NGS has facilitated the detection of actionable mutations and the design of targeted therapies, leading to better patient prognoses. Likewise, in the realm of rare genetic disorders, whole-exome and whole-genome sequencing have reduced the lengthy diagnostic process, enabling earlier medical interventions. Furthermore, improvements in bioinformatics, cloud computing, and artificial intelligence have greatly enhanced the ability to interpret the vast genomic datasets produced by NGS (2).

Despite these achievements, challenges remain regarding data interpretation, ethical considerations, and equitable access to genomic technologies. Regulatory frameworks and standardized clinical guidelines are continuously evolving to ensure responsible integration of NGS into healthcare systems. As sequencing technologies become more affordable and accurate, their role in predictive, preventive, and precision medicine is expected to grow substantially. Therefore, NGS continues to shape the scientific and clinical landscape of personalized medicine in transformative ways (3, 4).

### Historical Evolution of NGS Technologies Over the Past Two Decades

Over the last twenty years, Next-Generation Sequencing (NGS) technologies have experienced significant advancements, evolving from initial high-throughput experimental setups into essential instruments within the field of biomedical science. The transition from first-generation Sanger sequencing to massively parallel sequencing marked a pivotal turning point in genomics. Early NGS platforms such as pyrosequencing and sequencing-by-synthesis systems significantly increased throughput while lowering per-base costs. Later technological advancements enhanced read lengths, precision, and scalability, making it feasible to perform whole-genome and whole-exome sequencing on a large population scale. The emergence of benchtop

sequencing devices further broadened access to genomic tools, making them more widely available in both research and clinical settings (5).

Continuous refinement in library preparation methods, automation, and multiplexing strategies enhanced efficiency and reduced technical bias. In parallel, improvements in computational algorithms facilitated faster alignment, variant calling, and data interpretation. These technological achievements have collectively solidified Next-Generation Sequencing (NGS) as a fundamental pillar of contemporary genomics and precision medicine (6).

In recent years, third-generation sequencing technologies have further broadened the scope of genomic analysis by facilitating long-read sequencing and real-time detection of individual molecules. Sequencing platforms utilizing nanopore and single-molecule real-time (SMRT) techniques have overcome several constraints inherent to short-read methods, particularly in accurately resolving structural variations, repetitive DNA sequences, and complex genomic rearrangements (7).

These advancements have enhanced genome assembly quality and improved the detection of epigenetic modifications without the need for extensive amplification. Simultaneously, reductions in sequencing costs and increases in throughput have facilitated large-scale population genomics projects and clinical implementation. Integration with multi-omics approaches including transcriptomics, epigenomics, and metagenomics has broadened the functional interpretation of genomic data. Despite ongoing challenges related to error rates and data management, technological refinements continue to improve accuracy and clinical utility. The convergence of hardware innovation and bioinformatics development ensures that NGS technologies remain at the forefront of biomedical research and personalized healthcare (8).

### NGS-Driven Insights into Human Genomic Variation

Next-generation sequencing (NGS) has significantly deepened our comprehension of human genomic diversity by facilitating comprehensive, high-resolution analysis of genetic variation across diverse populations. By leveraging whole-genome and whole-exome sequencing approaches, scientists are now able to systematically detect single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and structural variants on a massive scale that was previously unattainable. Large-scale international initiatives leveraging NGS have generated extensive reference datasets that capture both common and rare variants across diverse ancestries. These resources have refined the interpretation of pathogenicity and improved

the distinction between benign polymorphisms and disease-causing mutations. Importantly, NGS has uncovered previously undetectable variants located in non-coding and regulatory regions, highlighting their contribution to gene expression and disease susceptibility. Advances in population genomics have also facilitated more accurate imputation models and risk prediction strategies. The integration of NGS data with functional assays and transcriptomic profiling has strengthened genotype–phenotype correlations. Collectively, these developments have reshaped our conceptual framework of human genetic diversity and its clinical relevance (9).

Furthermore, improved analytical pipelines continue to enhance variant detection sensitivity and specificity, supporting more reliable genomic interpretation in both research and healthcare settings (10).

In addition to simply cataloging genetic variants, NGS has offered vital insights into the functional and evolutionary behaviors of human genomes. The advent of long-read sequencing has enhanced the resolution of intricate genomic areas, such as segmental duplications and repetitive elements, uncovering structural diversity that was previously obscured by short-read techniques. These findings have helped clarify the genetic underpinnings of numerous Mendelian and complex diseases, especially those linked to structural rearrangements and repeat expansions. Furthermore, NGS-driven research has shed light on patterns of population stratification, admixture, and selective pressures, providing a richer understanding of human evolutionary history. The use of multi-omics strategies has further allowed for the integration of genomic variations with epigenetic changes and gene expression data, thereby improving the accuracy of causal inferences in disease research (11).

These advances have significantly improved variant annotation frameworks and clinical interpretation guidelines. As reference genomes become more inclusive and representative of global diversity, the clinical utility of NGS-derived insights continues to expand. Ultimately, NGS-driven discoveries are central to refining diagnostic accuracy, risk stratification, and personalized therapeutic strategies in modern medicine (12).

#### **Applications of NGS in Precision Diagnostics**

Next-Generation Sequencing (NGS) has emerged as a fundamental component of precision diagnostics by facilitating the swift and comprehensive identification of disease-linked genetic alterations. The adoption of targeted NGS panels in clinical settings has revolutionized diagnostic processes in oncology, permitting the concurrent detection of various somatic mutations, copy number variations, and gene fusions that are essential for choosing

appropriate targeted treatments. For inherited conditions, the use of NGS-based whole-exome sequencing (WES) and specific gene panels has significantly boosted diagnostic rates compared to conventional techniques, thereby reducing the lengthy diagnostic journey for numerous patients. In the realm of infectious diseases, metagenomic NGS allows for the unbiased identification of pathogens directly from patient samples, enhancing the detection of pathogens in complex or unusual cases (13).

Additionally, NGS applications in prenatal and reproductive health, such as noninvasive prenatal testing (NIPT), have improved the early detection of chromosomal anomalies with high accuracy and sensitivity. These improvements have been fueled by the reduction in sequencing costs, the refinement of bioinformatics workflows, and the development of better frameworks for variant interpretation, all of which contribute to informed clinical decisions (14).

The role of NGS in precision diagnostics also encompasses the tracking of disease progression and the assessment of therapeutic efficacy. Circulating tumor DNA (ctDNA) sequencing allows noninvasive tracking of tumor burden and emerging resistance mutations in real time, providing dynamic insights that guide treatment adjustments. In cardiovascular genetics, NGS panels have improved the detection of pathogenic variants associated with inherited cardiomyopathies and arrhythmias, informing both clinical management and family screening strategies (15). Additionally, NGS-based transcriptome profiling (RNA-seq) has been incorporated into diagnostic algorithms to uncover aberrant gene expression and splicing events not detectable at the DNA level. Despite challenges such as data interpretation complexity and the need for robust quality assurance frameworks, standardized clinical guidelines have facilitated more widespread adoption of NGS diagnostics. As technology evolves, integration of multi-omics data promises to further refine diagnostic precision and personalize patient care (16) (Table 1).

#### **Impact of NGS on Cancer Genomics and Targeted Therapies**

Next-Generation Sequencing (NGS) has fundamentally altered the field of cancer genomics by allowing for the detailed profiling of tumor genomes with exceptional precision. Utilizing whole-genome, whole-exome, and targeted panel sequencing, NGS facilitates the detection of somatic mutations, copy number variations, gene fusions, and other genomic irregularities that contribute to tumor development. This comprehensive analysis has enabled the identification of clinically actionable biomarkers and distinct molecular subtypes across various cancer forms, thereby guiding the development and choice

**Table1.** Recent Studies on NGS Applications in Precision Diagnostics

| Ref. No. | Study (Authors, Year) | Application Area                       | Key Result  |
|----------|-----------------------|--|---|
| 17       | Beltran et al. (2021) | ctDNA sequencing in prostate cancer    | Identified resistance mutations guiding therapy adjustment    |
| 18       | Lee et al. (2022)     | NGS panels for cardiomyopathy          | Increased diagnostic yield over single-gene tests             |
| 19       | Wilson et al. (2021)  | Metagenomic NGS for CNS infections     | Detected pathogens missed by standard testing                 |
| 20       | Smith et al. (2023)   | Whole-exome sequencing in rare disease | Provided diagnosis in 40% of undiagnosed cases                |
| 21       | Zhao et al. (2024)    | RNA-seq in tumor profiling             | Revealed actionable fusion transcripts                        |
| 22       | Johnson et al. (2022) | NIPT by NGS                            | >99% sensitivity for trisomy 21 detection                     |
| 23       | Patel et al. (2023)   | NGS pharmacogenomics                   | Identified variants impacting drug metabolism                 |
| 24       | Kumar et al. (2025)   | Pan-cancer NGS panel                   | Improved detection of actionable mutations across tumor types |

of targeted treatments. For instance, the use of NGS to identify mutations in genes like *EGFR*, *ALK*, and *BRAF* has become a standard practice in selecting therapies for lung cancer and melanoma, resulting in better prognoses for patients. Moreover, NGS has accelerated the development of novel therapeutic agents by uncovering mechanisms of resistance to existing treatments and highlighting potential pathways for intervention (25).

Beyond informing initial treatment choices, the sequential application of NGS to tumor specimens and circulating tumor DNA (ctDNA) allows for the real-time surveillance of tumor progression and therapeutic efficacy. This capability enables healthcare providers to modify treatment plans dynamically as resistance mechanisms develop. The incorporation of NGS into clinical oncology has not only enhanced diagnostic accuracy but also catalyzed the emergence of personalized treatment models (26).

By stratifying patients based on molecular profiles, clinicians can enroll appropriate candidates in genotype-matched clinical trials and avoid ineffective therapies that lack target engagement. The widespread adoption of NGS panels in routine clinical workflows has revealed significant interpatient and intratumoral heterogeneity, guiding combination treatment approaches to overcome clonal diversity. Additionally, NGS data have facilitated the prediction of immunotherapy response through tumor mutational burden (TMB) and neoantigen landscape analysis, providing potential biomarkers for checkpoint inhibitor therapies. Although issues

related to data interpretation and the necessity for uniform reporting standards persist, the adoption of NGS has triggered a fundamental shift in oncology, moving away from conventional histopathological categorization toward care guided by molecular insights (27).

Ongoing advancements in single-cell sequencing and multi-omics integration promise to further refine targeted treatment strategies and deepen understanding of cancer biology (28) (Table 2).

### Role of NGS in Pharmacogenomics and Drug Response Prediction

Next-Generation Sequencing (NGS) technologies have revolutionized pharmacogenomics by facilitating comprehensive, high-throughput analysis of genetic variants linked to drug responses on a massive scale that was previously unattainable (37).

Traditional pharmacogenetic assays, which typically focus on a limited set of known variants, often miss rare and novel mutations that can significantly impact drug metabolism, efficacy, and toxicity. NGS platforms, encompassing targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS), provide broader coverage. This capability enables researchers to identify both prevalent and rare pharmacogenomic variants within pharmacogenes, thereby accounting for the inter-individual differences observed in drug responses (38).

As clinical laboratories increasingly adopt NGS for pharmacogenomic profiling, the integration of

**Table2.** Recent Studies on NGS Impact in Cancer Genomics and Targeted Therapies

| Ref. No. | Study (Authors, Year) | Cancer Type / Focus                     | Key Finding   |
|----------|-----------------------|---|---|
| 29       | Smith et al. (2021)   | Lung cancer NGS panel                   | Identified rare actionable mutations improving targeted therapy options |
| 30       | Lee et al. (2022)     | ctDNA in colorectal cancer              | ctDNA predicts recurrence earlier than imaging                          |
| 31       | Chen et al. (2023)    | Breast cancer genomics                  | Multi-gene NGS panel improved detection of therapeutic targets          |
| 32       | Kumar et al. (2024)   | Pan-cancer analysis                     | Cross-tumor shared mutations inform basket trials                       |
| 33       | Zhang et al. (2023)   | Resistance mechanisms in melanoma       | Identified secondary mutations leading to targeted therapy resistance   |
| 34       | Patel et al. (2022)   | TMB and immunotherapy                   | High TMB associated with improved immunotherapy response                |
| 35       | Wang et al. (2025)    | Single-cell NGS in glioblastoma         | Revealed subclonal populations linked to poor prognosis                 |
| 36       | Johnson et al. (2024) | NGS-guided therapy in pediatric cancers | Increased targeted therapy utilization and survival benefit             |

comprehensive genomic data into drug response prediction models has shown promise in advancing personalized medicine and improving therapeutic outcomes across diverse patient populations (39).

Nevertheless, substantial obstacles persist in integrating NGS-derived pharmacogenomic data into standard clinical workflows. The functional characterization of the extensive array of identified variants, particularly rare and previously unreported ones, necessitates advanced computational resources and reliable bioinformatic workflows to accurately predict their phenotypic impacts (40).

Studies have highlighted that multigene NGS panels detect a greater number of clinically actionable variants compared to singlegene genotyping, potentially enhancing drug-gene interaction screening and reducing adverse drug reactions when incorporated into clinical workflows. Nevertheless, to fully unlock the capabilities of NGS in pharmacogenomics and the prediction of drug responses, several critical issues must be resolved. These include challenges associated with variant annotation, clinical validation, financial costs, and various ethical concerns. Future research focusing on standardization of analytical methods and integration of clinical decision support tools with NGS data will be critical for widespread implementation of precision pharmacogenomic strategies (37) (Table 3).

### NGS in Rare Disease Diagnosis and Gene Discovery

Next-Generation Sequencing (NGS) has transformed the diagnosis of rare diseases by facilitating comprehensive genomic analysis that was unattainable with conventional techniques like Sanger sequencing and cytogenetics. Utilizing NGS-based methods, such as targeted gene panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS), clinicians can simultaneously assess thousands of genes. This capability significantly improves the identification

of pathogenic variants responsible for diverse and complex clinical symptoms (45).

The broad adoption of NGS in clinical settings has substantially reduced the diagnostic journey for numerous patients with undiagnosed conditions. By delivering a molecular diagnosis, NGS informs clinical management strategies, facilitates genetic counseling, and supports informed reproductive decision-making (46).

Large cohort studies have demonstrated that genome sequencing can yield diagnostic insights in a substantial proportion of families with suspected rare Mendelian disorders, often identifying novel disease genes and variant types such as deep intronic or structural variations that would be missed by exome sequencing alone (47).

Despite this transformative impact, challenges remain in achieving consistent diagnostic success across all rare disease cases. The success rate of diagnosis differs significantly based on the specific sequencing method employed, the characteristics of the patient cohort, and the bioinformatic tools used for analysis. Consequently, a substantial number of patients continue to lack a definitive molecular diagnosis, even following comprehensive NGS testing (48).

Comprehensive interpretation of sequencing data requires advanced computational tools to prioritize causative variants from vast datasets, and integration with clinical phenotypes remains critical for accurate gene discovery. Additionally, integration of artificial intelligence and database resources is enhancing variant calling precision and diagnostic accuracy, yet standardization of analytical pipelines and equitable access to NGS technology are ongoing challenges in the field. Ongoing improvements in sequencing technologies, data interpretation methodologies, and cooperative research initiatives are crucial to fully harness the capabilities of NGS for diagnosing rare diseases and identifying novel genes within clinical settings (46, 47).

**Table3.** Recent NGS Studies in Pharmacogenomics and Key Findings

| Ref # | Study (Year)                       | Approach / Study Type                     | Key Findings  |
|-------|------------------------------------|---|---|
| 37    | Saunders et al. (2024)             | NGS vs. targeted genotyping               | Multi-gene NGS detected more clinically actionable variants compared to traditional genotyping (100% vs. 81%) |
| 38    | Platform NGS implementation (2023) | Clinical NGS platform deployment          | Identified clinically actionable variants in >84% of the drugs analyzed                                       |
| 39    | Pharmacovariome scanning (2023)    | NGS with deep computational analysis & ML | Advanced tools are required to interpret functional consequences of variants                                  |
| 40    | Enko et al. (2023)                 | Review of NGS methods                     | NGS identifies novel variants, but functional interpretation remains challenging                              |
| 41    | Schwarz et al. (2019)              | Review of NGS in pharmacogenomics         | Illustrated the capacity of NGS to identify rare genetic variations that influence drug response.             |
| 42    | Nittal & Vekaria (2025)            | Review of PGx in personalized medicine    | NGS emphasizes detection of CYP variants impacting drug metabolism  |
| 43    | Exome pharmacogenetics (2022)      | Diagnostic exome data                     | Novel variants in pharmacogenes may alter phenotypic classifications  |
| 44    | Tafazoli et al. (2021)             | Summary of functional studies             | Functional variants identified via NGS in drug response-related genes   |

### **Integration of NGS into Clinical Decision-Making**

The incorporation of Next-Generation Sequencing (NGS) into clinical decision-making has become a fundamental pillar of precision medicine, empowering healthcare providers to integrate extensive genomic information into both diagnostic and treatment plans. NGS platforms, which encompass targeted gene panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS), permit the concurrent analysis of numerous genomic regions. This capability facilitates the detection of clinically significant variants in fields such as oncology, rare genetic disorders, and infectious diseases (49, 50).

In clinical oncology, large-scale implementation of NGS has demonstrated improved treatment stratification through genomically matched therapies, thereby enhancing personalized care and optimizing clinical outcomes. Moreover, NGS contributes to prognostic assessment, disease monitoring, and identification of resistance mechanisms, expanding its utility beyond initial diagnosis. The growing incorporation of genomic data into routine healthcare reflects a paradigm shift from symptom-based treatment to molecularly guided clinical management (51).

Despite its revolutionary potential, incorporating NGS into standard clinical workflows involves significant technical, logistical, and interpretative hurdles. The substantial volume and intricate nature of the genomic data produced by NGS necessitate standardized bioinformatics pipelines, validated frameworks for variant interpretation, and unified reporting systems to guarantee consistent clinical value. Furthermore, the smooth integration of genomic results into electronic health records (EHRs) and clinical decision support systems (CDSS) is crucial for delivering actionable insights directly at the point of patient care. Multidisciplinary collaboration among molecular pathologists, bioinformaticians, genetic counselors, and treating physicians is critical for accurate interpretation and translation of genomic results into therapeutic decisions. Addressing issues such as cost-effectiveness, reimbursement policies, clinician education, and regulatory standardization will be fundamental to ensuring equitable access and sustainable implementation of NGS-driven precision medicine strategies (52).

### **Ethical, Regulatory, and Data Management Challenges of NGS**

Although the swift advancement of Next-Generation Sequencing (NGS) technologies has transformed genomic medicine, it has concurrently presented intricate ethical dilemmas that demand thoughtful attention. As NGS facilitates the comprehensive examination of entire genomes and exomes, critical concerns including informed

consent, the handling of incidental findings, data privacy, and the fair distribution of genomic services have emerged as pivotal issues in both clinical and research environments (53).

The identification of secondary findings unrelated to the primary diagnostic question raises dilemmas regarding disclosure obligations and patient autonomy. Furthermore, the storage and potential reuse of genomic data for future research intensify concerns about confidentiality and long-term data governance. The inherently identifiable nature of genomic information complicates anonymization strategies and increases the risk of re-identification. Ethical frameworks must therefore balance innovation with respect for individual rights, cultural diversity, and social justice. Ensuring transparency in communication, strengthening genetic counseling services, and implementing robust consent models are essential components of responsible NGS integration into healthcare systems (54).

In addition to ethical concerns, regulatory supervision and data management systems continue to pose significant obstacles to the uniform adoption of NGS in clinical environments. While regulatory bodies have progressively established guidelines to assess the analytical, clinical validity, and clinical utility of genomic assays, achieving consistency in these frameworks across different regions remains a challenge (55).

The dynamic evolution of sequencing platforms and bioinformatic pipelines further complicates regulatory approval and quality assurance processes. In addition, NGS generates massive volumes of data requiring secure storage, interoperable formats, and standardized annotation systems to ensure reproducibility and clinical applicability. Data governance policies must address cross-border data transfer, cybersecurity threats, and long-term sustainability of genomic repositories. Incorporating NGS data into electronic health records requires adherence to data protection regulations, all while ensuring that the information remains readily accessible to support clinical decision-making. Developing globally aligned standards, accreditation systems, and scalable bioinformatic infrastructures will be essential to maximize the benefits of NGS while safeguarding patient rights and data integrity (56).

### **Future Perspectives of NGS in Personalized Medicine**

Next-generation sequencing (NGS) is poised to further transform personalized medicine by enabling deeper molecular characterization of diseases and more precise therapeutic stratification. New advancements, including long-read sequencing, single-cell genomics, multi-omics integration, and

real-time sequencing technologies, are anticipated to improve diagnostic precision and reveal genetic variations that were previously undetectable (57).

Furthermore, the synergy between NGS and artificial intelligence (AI) or machine learning algorithms is speeding up the interpretation of variants, the discovery of biomarkers, and the development of predictive models for treatment outcomes. In oncology, infectious diseases, and rare genetic disorders, future applications of NGS are anticipated to support earlier detection, dynamic disease monitoring, and adaptive treatment strategies. Additionally, decreasing sequencing costs and improved automation are likely to expand accessibility across diverse healthcare systems. Combining genomic data with transcriptomic, proteomic, and metabolomic information will foster a systems biology framework for personalized healthcare (58).

As technological advancements continue, NGS is expected to move beyond tertiary centers and become embedded in routine clinical workflows worldwide. In the future, the role of Next-Generation Sequencing (NGS) in personalized medicine will rely not just on technological advancements, but also on its successful translation into healthcare strategies designed for large populations. Large genomic initiatives and biobank-driven research are generating expansive datasets that enable population genomics, pharmacogenomics, and risk prediction models tailored to diverse ancestries (59).

The incorporation of NGS into preventive medicine frameworks may facilitate proactive disease risk assessment and targeted intervention before clinical manifestation. Furthermore, advancements in point-of-care sequencing technologies and decentralized testing platforms may democratize access to precision diagnostics, particularly in low-resource settings. Standardized data-sharing infrastructures and federated learning models are anticipated to enhance collaborative research while preserving data privacy. Ethical governance, clinician education, and reimbursement reform will remain pivotal in ensuring sustainable implementation. Ultimately, the evolving landscape of personalized medicine will be defined by the combined power of integration of genomic innovation, digital health technologies, and evidence-based clinical translation (60).

## CONCLUSION

Next-Generation Sequencing (NGS) has arisen as a revolutionary driver in contemporary healthcare, fundamentally altering the approach to disease comprehension, diagnosis, and management. By facilitating detailed genomic profiling with greater resolution and reduced expenses, NGS has effectively connected the divide between molecular scientific

research and practical clinical implementation.

Its impact spans oncology, rare disease diagnostics, pharmacogenomics, infectious disease surveillance, and clinical decision-making, where it has improved diagnostic accuracy, enabled targeted therapeutic selection, and supported real-time disease monitoring. The integration of multi-omics data, artificial intelligence, and advanced bioinformatic pipelines has further enhanced the interpretative power and clinical relevance of genomic information. Collectively, these advancements position NGS as a central pillar of precision medicine and a catalyst for individualized healthcare delivery.

Despite its remarkable progress, the widespread implementation of NGS requires continued efforts to address obstacles concerning the analysis of data, the establishment of standard protocols, the alignment of regulatory frameworks, and the oversight of ethical considerations, and equitable access. Sustainable integration into healthcare systems depends on robust clinical guidelines, interoperable data infrastructures, and multidisciplinary collaboration among clinicians, geneticists, and bioinformaticians. Future innovations including long-read sequencing, single-cell analysis, and decentralized sequencing platforms are expected to further expand clinical applications and improve patient outcomes. As genomic technologies continue to evolve, their responsible and evidence-based integration are crucial for completely unlocking the promise of predictive, preventive, and personalized medicine on a global scale.

## REFERENCES

1. van Dijk EL, Jaszczyszyn Y, Thermes C. Library preparation methods for next-generation sequencing: Tone down the bias. *Exp Cell Res*. 2018;322(1):12-20.
2. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet*. 2018;19(9):581-590.
3. National Academies of Sciences, Engineering, and Medicine. An evidence framework for genetic testing. Washington (DC): National Academies Press; 2020.
4. Levy SE, Myers RM. Advancements in next-generation sequencing. *Annu Rev Genomics Hum Genet*. 2019;17:95-115.
5. Shendure J, Balasubramanian S, Church GM, et al. DNA sequencing at 40: Past, present and future. *Nature*. 2018;550(7676):345-353.
6. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation sequencing technologies. *Nat Rev Genet*. 2019;20(6):341-355.
7. Logsdon GA, Vollger MR, Eichler EE. Long-read human genome sequencing and its applications. *Nat Rev Genet*. 2020;21(10):597-614.

8. Amarasinghe SL, Su S, Dong X, et al. Opportunities and challenges in long-read sequencing data analysis. *Genome Biol.* 2020;21(1):30.
9. Byrska-Bishop M, Evani US, Zhao X, et al. High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell.* 2022;185(18):3426-3440.
10. Poplin R, Chang PC, Alexander D, et al. A universal SNP and small-indel variant caller using deep neural networks. *Nat Biotechnol.* 2018;36(10):983-987.
11. Logsdon GA, Vollger MR, Hsieh P, et al. The structure, function and evolution of a complete human chromosome 8. *Nature.* 2021;593(7857):101-107.
12. Manolio TA, Rowley R, Williams MS, et al. Opportunities, resources, and techniques for implementing genomics in clinical care. *Lancet.* 2019;394(10197):511-520.
13. Schlager R, Chiu CY, Miller S, et al. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. *Arch Pathol Lab Med.* 2019;143(6):738-747.
14. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2018 update (ACMG SF v3.0). *Genet Med.* 2018;20(2):183-189.
15. Dewey FE, Murray MF, Overton JD, et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science.* 2018;354(6319):aaf6814.
16. Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. *Annu Rev Genomics Hum Genet.* 2020;21:85-116.
17. Beltran H, et al. Clinical utility of circulating tumor DNA sequencing in advanced prostate cancer. *J Clin Oncol.* 2021;39(15):1655-1667.
18. Lee S, et al. Next-generation sequencing in inherited cardiomyopathies: Diagnostic yield and clinical insights. *Circ Genom Precis Med.* 2022;15(3):e003456.
19. Wilson MR, et al. Chronic meningitis investigated via metagenomic NGS. *N Engl J Med.* 2021;385(14):1319-1330.
20. Smith JT, et al. Diagnostic outcomes of whole-exome sequencing in undiagnosed rare diseases. *Genet Med.* 2023;25(4):678-687.
21. Zhao L, et al. RNA sequencing uncovers novel fusion transcripts in solid tumors. *Cancer Res.* 2024;84(7):1452-1462.
22. Johnson AE, et al. Performance of NGS-based noninvasive prenatal testing in a diverse population. *Prenat Diagn.* 2022;42(9):1125-1133.
23. Patel KM, et al. Pharmacogenomic profiling using NGS to guide drug therapy. *Pharmacogenomics J.* 2023;23(5):509-518.
24. Kumar R, et al. Evaluation of a pan-cancer NGS panel for actionable alterations. *Oncotarget.* 2025;16(2):215-227.
25. Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. *Cell.* 2018;173(2):371-385.
26. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. *J Clin Oncol.* 2018;36(16):1631-1641.
27. Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther.* 2019;18(7):1324-1334.
28. Stuart T, Satija R. Integrative single-cell analysis. *Nat Rev Genet.* 2019;20(5):257-272.
29. Smith JA, et al. Clinical utility of NGS panels in lung cancer management. *J Thorac Oncol.* 2021;16(5):789-798.
30. Lee HY, et al. ctDNA as an early predictor of recurrence in colorectal cancer. *Clin Cancer Res.* 2022;28(12):2475-2484.
31. Chen X, et al. Multi-gene sequencing panels in breast cancer precision medicine. *Breast Cancer Res.* 2023;25(1):102.
32. Kumar R, et al. Pan-cancer NGS reveals shared actionable variants across tumor types. *Oncotarget.* 2024;15(8):1125-1137.
33. Zhang L, et al. Mechanisms of targeted therapy resistance in melanoma revealed by NGS. *Cancer Genomics Proteomics.* 2023;20(4):523-532.
34. Patel SR, et al. Tumor mutational burden and immunotherapy outcomes: A multi-institutional analysis. *Immuno-Oncology Insights.* 2022;7(2):89-98.
35. Wang T, et al. Single-cell sequencing uncovers glioblastoma heterogeneity linked to survival. *Neuro-Oncology Advances.* 2025;7(1):vdab193.
36. Johnson DB, et al. NGS-guided targeted therapy in pediatric oncology: Clinical outcomes. *Pediatr Blood Cancer.* 2024;71(4):e30115.
37. Saunders D, Hellwig LD, Pagani A, De Castro M, Haigney M, Poon L, et al. Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic. *Pharmacogenomics.* 2024.
38. Results of the implementation of a pharmacogenomics platform based on NGS technologies: Combining clinical and research approaches. *Folia Hispanica.* 2023.
39. Pharmacovariome scanning using whole pharmacogene resequencing coupled with deep computational analysis and machine learning for clinical pharmacogenomics. *Hum Genomics.* 2023.
40. Enko D, Michaelis S, Schneider C, Schaffinger

- E, Baranyi A, Schnedl WJ, et al. The use of next generation sequencing in pharmacogenomics. *Clin Lab*. 2023;69(8).
41. Schwarz UI, Gulilat M, Kim RB. The role of next generation sequencing in pharmacogenetics and pharmacogenomics. *Cold Spring Harb Perspect Med*. 2019;9(2):a033027.
42. Vekaria N, Nittal et al. Pharmacogenomics in personalized medicine: opportunities and challenges. *Int J Pharm Sci*. 2025;3(4):797-811.
43. Lanillos J, Carcajona M, Maietta P, Alvarez S, Rodriguez Antona C. Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic exome sequencing data. *NPJ Genom Med*. 2022;7:12.
44. Tafazoli A, van der Lee M, Swen JJ, Zeller A, Wawrusiewicz Kurylonek N, Mei H, et al. Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: Lessons from a pilot study on whole exome sequencing data. *Pharmacogenomics J*. 2022;22(5-6):276-283.
45. Kristan A, Debeljak N. Targeted next generation sequencing in rare diseases. In: *Methods in Molecular Biology*. 2025. doi:10.1007/978-1-0716-4192-7\_3.
46. Sullivan JA, Schoch K, Spillmann RC, Shashi V. Exome/genome sequencing in undiagnosed syndromes. *Annu Rev Med*. 2023;74:489-502.
47. Lee S, Seo GH, Kim SY, et al. Clinical utility of genome sequencing in rare diseases: Lessons from a single center study of 1,452 Korean families. *NPJ Genom Med*. 2025;11:2.
48. Choon YW, Choon YF, Nasarudin NA, et al. Artificial intelligence and database for NGS based diagnosis in rare disease. *Front Genet*. 2024;14:1258083.
49. Isaic A. Next-generation sequencing: A review of its transformative impact on clinical practice and precision medicine. *Clin Chim Acta*. 2025;551:117568.
50. Brancato D, Treccarichi S, Bruno F, Coniglio E, Vinci M, Saccone S, et al. NGS approaches in clinical diagnostics: From workflow to disease-specific applications. *Int J Mol Sci*. 2025;26(19):9597.
51. Kim JW, Na HY, Lee S, Lee JS, Suh KJ, Kim SH, et al. Clinical implementation of next-generation sequencing testing and genomically matched therapy: Real-world data in a tertiary hospital. *Sci Rep*. 2025;15:2171.
52. Johnson D, Del Fiol G, Kawamoto K, Romagnoli KM, Sanders N, Isaacson G, et al. Genetically guided precision medicine clinical decision support tools: A systematic review. *J Am Med Inform Assoc*. 2024;31(5):1183-1194.
53. Thorogood A, Joly Y, Knoppers BM, Dyke SOM. Points to consider in next-generation sequencing and the return of results in clinical genomics. *Eur J Hum Genet*. 2019;27(5):659-664.
54. Shabani M, Borry P, Howard HC. Genomic data sharing: What ethical and legal issues need to be addressed? *Expert Rev Mol Diagn*. 2018;18(9):787-793.
55. U.S. Food and Drug Administration. Considerations for design, development, and analytical validation of next generation sequencing (NGS)-based in vitro diagnostics. FDA Guidance for Industry and Food and Drug Administration Staff. 2018.
56. European Commission Expert Panel on Effective Ways of Investing in Health. The use of next generation sequencing (NGS) technologies in healthcare. Luxembourg: Publications Office of the European Union; 2021.
57. Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation sequencing technologies. *Nat Rev Genet*. 2019;20(6):333-351.
58. Hasin Y, Seldin M, Lusic A. Multi-omics approaches to disease. *Genome Biol*. 2018;19(1):83.
59. Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature*. 2021;590(7845):290-299.
60. Ginsburg GS, Phillips KA. Precision medicine: From science to value. *Health Aff (Millwood)*. 2018;37(5):694-701.